SPPI / Spectrum Pharmaceuticals, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35006 Spectrum Pharmaceuticals, Inc. (Exact name of registrant as specif

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No.

As filed with the Securities and Exchange Commission on September 26, 2023

As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement File No.

Amended and Restated Certificate of Incorporation of Spectrum Pharmaceuticals, Inc., dated July 31, 2023

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SPECTRUM PHARMACEUTICALS, INC. (a Delaware corporation) ARTICLE I NAME The name of the corporation is Spectrum Pharmaceuticals, Inc. (the “Corporation”). ARTICLE II AGENT The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The nam

Amended and Restated Bylaws of Spectrum Pharmaceuticals, Inc, dated July 31, 2023

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SPECTRUM PHARMACEUTICALS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Spectrum Pharmaceuticals, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”). Section 1.2 Other Offices. The Corporation may also

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected

EX-99.1 Exhibit 99.1 Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth Across All Products Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., July 31, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 SPECTRUM PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commi

Assertio Holdings, Inc Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretiv

EX-99.1 Exhibit 99.1 Assertio Holdings, Inc Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill., and BOSTON — July 27, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 SPECTRUM PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant □ Check the appropriate box: □ Preliminary Proxy Statement □ Confidential, for Use of the Commission Only (as permit

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Boston, MA, May 17, 2023 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical Company focused on novel and targeted oncology announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 SPECTRUM PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SPECTRUM PHARMACEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 ASSERTIO HOLDINGS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 ASSERTIO HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 01-39294 85-0598378 (State or Other Jurisdiction of Incorporation) (Commission File

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update — Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 — — Company to be acquired by Assertio Holdings, Inc., delivering value to stakeho

EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update — Q1 2023 net sales of $15.6 million, an increase of 54% compared to Q4 2022 — — Company to be acquired by Assertio Holdings, Inc., delivering value to stakeholders in an all stock and contingent value rights (CVR) transaction — — Transaction expected to close in Q3 2023 — BOSTON—(BUSINE

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Sp

Exhibit 99.1 Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum Pharmaceuticals in All Stock and CVR Transaction, Expected to be Significantly Accretive to Adjusted EPS and Operating Cash Flow i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE C OMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REP

Table of Contents UNITED STATES SECURITIES AND EXCHANGE C OMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Stream

Exhibit 99.1 Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and G

Agreement and Plan of Merger, dated as of April 24, 2023, by and among Spectrum Pharmaceuticals, Inc., Assertio Holdings, Inc. and Spade Merger Sub 1, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Form 8-K filed on April 25, 2023 (File No. 001-35006))

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among ASSERTIO HOLDINGS, INC. SPADE MERGER SUB 1, INC. and SPECTRUM PHARMACEUTICALS, INC. Dated as of April 24, 2023 TABLE OF CONTENTS Page Article I THE Merger 2 Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Effects of the Merger 3 Section 1.4 Certificate of Incorporation and Bylaws 3 Section 1.5 Directors; Officers 3 Section 1

Merger Agreement, dated as of April 24, 2023, by and among Spectrum Pharmaceuticals, Inc., Assertio Holdings Inc. and Spade Merger Sub 1, Inc. (Form of CVR Agreement included as Exhibit B thereto) (The disclosure letters and exhibits to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Registrant will furnish copies of such disclosure letters and exhibits to the U.S. Securities and Exchange Commission upon request by the Commission).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among ASSERTIO HOLDINGS, INC. SPADE MERGER SUB 1, INC. and SPECTRUM PHARMACEUTICALS, INC. Dated as of April 24, 2023 TABLE OF CONTENTS Page Article I THE Merger 2 Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Effects of the Merger 3 Section 1.4 Certificate of Incorporation and Bylaws 3 Section 1.5 Directors; Officers 3 Section 1

Agreement and Plan of Merger, dated April 24, 2023, by and among Assertio Holdings, Inc., Spade Merger Sub 1, Inc. and Spectrum Pharmaceuticals, Inc. (Form of CVR Agreement included as Exhibit B thereto)*

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among ASSERTIO HOLDINGS, INC. SPADE MERGER SUB 1, INC. and SPECTRUM PHARMACEUTICALS, INC. Dated as of April 24, 2023 TABLE OF CONTENTS Page Article I THE Merger 2 Section 1.1 The Merger 2 Section 1.2 Closing; Effective Time 2 Section 1.3 Effects of the Merger 3 Section 1.4 Certificate of Incorporation and Bylaws 3 Section 1.5 Directors; Officers 3 Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (Date of earliest event reported) ASSERTIO HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (Date of earliest event reported) ASSERTIO HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39294 85-0598378 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (Date of earliest event reported) ASSERTIO HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (Date of earliest event reported) ASSERTIO HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39294 85-0598378 (State or Other Jurisdiction of Incorporation) (Commission F

Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Stream

Exhibit 99.1 Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Comm

Press Release, jointly issued by Spectrum Pharmaceuticals, Inc. and Assertio Holdings Inc. dated April 25, 2023.

Exhibit 99.1 Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and G

Assertio Holdings and Spectrum Pharmaceuticals Transaction April 25, 2023

Exhibit 99.1 Assertio Holdings and Spectrum Pharmaceuticals Transaction April 25, 2023 Corporate Speakers · Matt Kreps; Darrow Associates Investor Relations; Managing Director · Dan Peisert; Assertio Holdings, Inc.; President and Chief Executive Officer · Tom Riga; Spectrum Pharmaceuticals, Inc.; President and Chief Executive Officer Participants · Thomas Flaten; Lake Street; Analyst · Ed White; H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction (Commission (IRS Employ

Fourth Amended and Restated Bylaws

EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF SPECTRUM PHARMACEUTICALS, INC. a Delaware corporation (effective March 30, 2023) ARTICLE I OFFICES Section 1 Registered Office. The registered office of the Corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2 Other Offices. The Corporation may also have offices at such other places both wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2023 SPECTRUM PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name o

Form of Non-NEO Stock Option Award under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2018 LONG-TERM INCENTIVE PLAN STOCK OPTION AWARD Spectrum Pharmaceuticals, Inc. (the “Company”) hereby grants to the Participant named below a stock option (the “Option”) to purchase any part or all of the number of Shares that are covered by this Option, as specified below, at the exercise price specified below, under the Spectrum Pharmaceuticals, Inc

Second Amendment to Supply Agreement, dated as of January 1, 2022, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

First Amendment to License, Development and Supply Agreement, dated as of February 28, 2018, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Form of Non-NEO Restricted Stock Unit Award under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Spectrum Pharmaceuticals, Inc. (the “Company”) hereby grants to the Participant named below Restricted Stock Units (the “RSUs”) covering the number of Shares specified below (the “Award”), under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the “Plan”). This Award is governed

Form of NEO Restricted Stock Unit Award under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.

SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Spectrum Pharmaceuticals, Inc. (the “Company”) hereby grants to the Participant named below Restricted Stock Units (the “RSUs”) covering the number of Shares specified below (the “Award”), under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the “Plan”). This Award is governed

Form of NEO Stock Option Award under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2018 LONG-TERM INCENTIVE PLAN STOCK OPTION AWARD Spectrum Pharmaceuticals, Inc. (the “Company”) hereby grants to the Participant named below a stock option (the “Option”) to purchase any part or all of the number of Shares that are covered by this Option, as specified below, at the exercise price specified below, under the Spectrum Pharmaceuticals, Inc

Subsidiaries of Registrant.

EXHIBIT 21.1 List of Subsidiaries SUBSIDIARY/AFFILIATE NAME INCORPORATION Spectrum Oncology Private Limited India Spectrum Pharmaceuticals International Holdings, LLC Delaware Allos Therapeutics, Inc. Delaware Spectrum Pharmaceuticals Cayman, L.P. (1% Spectrum Pharmaceuticals International Holdings, LLC and 99% Spectrum Pharmaceuticals, Inc.) Cayman Islands Spectrum Pharmaceuticals, B.V. Netherlan

First Amendment to Supply Agreement, dated as of December 6, 2019, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Second Amendment to License, Development and Supply Agreement, dated as of January 1, 2022, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Supply Agreement, dated as of February 28, 2018, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

License, Development and Supply Agreement, dated as of October 8, 2014, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd

Execution Version [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update -- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to

Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update - First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection - - Q4 and full year net sales of $10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 SPECTRUM PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction (Commission (IRS Employ

SPPI / Spectrum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Spectrum Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 84763A108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 SPECTRUM PHARMAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Co

Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services Boston, MA, February 8, 2023 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON

Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results — Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million — — Cash, cash equiv

EX-99.1 2 d745957dex991.htm EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results — Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million — — Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runwa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 SPECTRUM PHARMAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2022 SPECTRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (C

Spectrum Pharmaceuticals Announces Management Changes

EX-99.1 4 d437750dex991.htm EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Announces Management Changes Boston, MA, January 4, 2023 – Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue oth

Consulting Agreement, dated January 2, 2023, between Spectrum Pharmaceuticals, Inc. and Francois Lebel.

EX-10.2 3 d437750dex102.htm EX-10.2 Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into as of January 2, 2023 (the “Effective Date”), by and between Spectrum Pharmaceuticals, Inc., a Delaware corporation, located at 2 Atlantic Avenue, 6th Floor, Boston, MA 02110 (“Spectrum”), and Francois Lebel (“Consultant”). AGREEMENT In consideration of the covenants se

Confidential Separation Agreement and General Release, dated December 31, 2022, between Spectrum Pharmaceuticals, Inc. and Francois Lebel.

Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (this ?Agreement?) is hereby entered into by and between Francois Lebel, an individual (the ?Employee?), and Spectrum Pharmaceuticals, Inc., on behalf of itself and all of its affiliated entities (collectively, the ?Company?). 1. Effective Date. Except as otherwise provided

As filed with the Securities and Exchange Commission on November 22, 2022

S-8 POS As filed with the Securities and Exchange Commission on November 22, 2022 Registration No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF

15-12G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35006 Spectrum Pharmaceuticals, Inc. 401(k) Plan as amended and restated Spect

As filed with the Securities and Exchange Commission on November 22, 2022

S-8 POS As filed with the Securities and Exchange Commission on November 22, 2022 Registration No.

As filed with the Securities and Exchange Commission on November 22, 2022

S-8 POS As filed with the Securities and Exchange Commission on November 22, 2022 Registration No.

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) SPECTRUM PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on November 14, 2022

S-8 As filed with the Securities and Exchange Commission on November 14, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 S

Form of Stock Option Award Agreement under the Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan

US-DOCS\136538652.1 SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION AWARD Spectrum Pharmaceuticals, Inc. (the ?Company?) hereby grants to the Participant named below a stock option (the ?Option?) to purchase any part or all of the number of Shares that are covered by this Option, as specified below, at the exercise price specified below, u

Form of Restricted Stock Unit Award Agreement under the Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan

spectrum-formofrsuawarda US-DOCS\136537642.1 SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD Spectrum Pharmaceuticals, Inc. (the “Company”) hereby grants to the Participant named below Restricted Stock Units (the “RSUs”) covering the number of Shares specified below (the “Award”), under the Spectrum Pharmaceuticals, Inc. 202

Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan

a2022employmentinducemen Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan Section 1. PURPOSE The purposes of this Spectrum Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”) are to encourage selected Eligible Persons of the Company and its Affiliates to acquire a proprietary interest in the growth and performance of the Company, to gene

Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update -- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host w

Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available - - Cash runway expected to extend through 2024 - - Management to host webcast and conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 SPECTRUM PHARMACE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 SPECTRUM PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Form of Warrant

Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN

Loan and Security Agreement, dated as of September 21, 2022, by and among Spectrum Pharmaceuticals, Inc., the other borrowers party thereto, the lenders party thereto and SLR Investment Corp. as collateral agent

Exhibit 10.1 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of September 21, 2022 (the ?Effective Date?) among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3rd Floor, New York, NY 10022 (?SLR?), as collateral agent

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Exhibit 99.2 Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting BOSTON ? September 22, 2022 ? Spectrum Pharmaceuticals (NasdaqGS: SPPI) (?Spectrum? or the ?Company?), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration?s (?FDA?) Oncologic Drugs Advisory

Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing — Multiple tranche debt financing provides Spectrum with up to $65 million — — Funding provides additional capital to optimize co

Exhibit 99.1 Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing ? Multiple tranche debt financing provides Spectrum with up to $65 million ? ? Funding provides additional capital to optimize commercial launch of ROLVEDON? ? ? Cash runway extended through 2024 ? BOSTON ? September 23, 2022 - Spectrum Pharmaceuticals, Inc. (Nasdaq

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 SPECTRUM PHARMACEUTICALS, INC.

First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to launch wit

Exhibit 99.1 Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON? (eflapegrastim-xnst) Injection First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON? developed using proprietary LAPSCOVERY? technology with a differentiated molecular structure and proven safety and efficacy profile Commercial team ready to launch with product available in the fourth quarter BOS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTR

Executive Employment Agreement, dated April 19, 2022, by and between Spectrum Pharmaceuticals, Inc. and Nora Brennan

1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this ?Agreement?) is dated as of April 19, 2022, by and between Spectrum Pharmaceuticals, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrast

Exhibit 99.1 Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Spectrum Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on June 30, 2022

As filed with the Securities and Exchange Commission on June 30, 2022 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 A. Full title of the plan and the add

Amended and Restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

Exhibit 10.1 Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (As Amended and Restated Effective April 23, 2022) Section 1. PURPOSE The purposes of this Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the ?Plan?) are to encourage selected Eligible Persons of the Company and its Affiliates to acquire a proprietary interest in the growth and performance of the Company, to g

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer HENDERSON, Nev. ? May 11, 2022 ? Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan as Chief Financial Officer effective May 25, 2022. Ms. Brennan has served on Spectrum?s Board of Directors and as Chairpe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of Novem

Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment na?ve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECT

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors HENDERSON, Nev. – May 5, 2022 – Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate develo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Description of Equity Securities Registered under Section 12 of the Exchange Act.

Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK WE MAY OFFER General Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The following description of our common stock and preferred stock, together with the additional information included in any applicable prospectus supplements or rel

Subsidiaries of Registrant.

EXHIBIT 21.1 List of Subsidiaries SUBSIDIARY/AFFILIATE NAME INCORPORATION Spectrum Oncology Private Limited India Spectrum Pharmaceuticals International Holdings, LLC Delaware Allos Therapeutics, Inc. Delaware Spectrum Pharmaceuticals Cayman, L.P. (1% Spectrum Pharmaceuticals International Holdings, LLC and 99% Spectrum Pharmaceuticals, Inc.) Cayman Islands Spectrum Pharmaceuticals, B.V. Netherlan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name o

Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 2

Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment na?ve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 SPECTRUM PHARMACEUTICALS, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors

Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors HENDERSON, Nev.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 SPECTRUM PHARMACEUTICALS, INC.

AGREEMENT

Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, $0.001 par value, of Spectrum Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd

SPPI / Spectrum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SPPI / Spectrum Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SPECTRUM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 84763A108 (CUSIP Number) FEBRUARY 2, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Spectrum Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 84763A108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule

SPPI / Spectrum Pharmaceuticals, Inc. / Hanmi Pharmaceutical Co., Ltd. - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Spectrum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 84763A108 (CUSIP Number) Hanmi Pharmaceutical Co., Ltd. 14 Wiryeseong-daero, Songpa-gu Seoul, 05545, Republic of Korea +82 (2) 410 8796

Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical

Exhibit 99.1 Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical January 4, 2022 HENDERSON, Nev.?(BUSINESS WIRE)?Jan. 4, 2022? Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Securities Purchase Agreement, dated as of January 3, 2022, by and between Hanmi Pharmaceutical Co., Ltd. and Spectrum Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed with the SEC on January 6, 2022).

Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of January 3, 2022 by and among SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and HANMI PHARMACEUTICAL CO., LTD., a South Korean corporation (the ?Investor?). RECITALS A. The Company and the Investor are executing and delivering th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 S

Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohor

Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Update Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell line ROLONTIS? (eflapegrastim) CRL manufacturing deficiencies expected to be remediated by the end of the year Management to host webcast and conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTR

Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remedia

Spectrum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Update Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS? (eflapegrastim) Management to host webcast and conference call today at 4:30 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

July 19, 2021

July 19, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Laura Crotty 100 F Street, NE Washington, D.C. 20549 Re: Spectrum Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-257876 (the ?Registration Statement?) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as ame

As filed with the Securities and Exchange Commission on July 13, 2021

Table of Contents As filed with the Securities and Exchange Commission on July 13, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ¨ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 A. Full title of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 A. Full title of the plan and the add

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Letter from Deloitte & Touche LLP addressed to the Securities Exchange Commission, dated June 2, 2021.

Exhibit 16.1 June 2, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Spectrum Pharmaceuticals, Inc.?s Form 8-K dated June 2, 2021, and have the following comments: 1. We agree with the statements made in the second, third, and fourth paragraphs of 4.01(a). 2. We have no basis on which to agree or disagree with the s

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS? manufacturing facility scheduled for May 2021 Management to host webcast and conference call today at 4:30 p.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CASI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CASI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 14757U109 (CUSIP Number) Kurt Gustafson Executive Vice President and Chief Financial Officer Spectrum Pharmaceuticals, Inc. 11500 South E

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) Three Months Ended December 31, Twelve Months Ended December 31, 2020 2019 2020 2019 Revenues $ — $ — $ — $ — Operating costs and

EX-99.1 2 exhibit991q420inancialresu.htm EX-99.1 SPECTRUM PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2020 2019 2020 2019 Revenues $ — $ — $ — $ — Operating costs and expenses: Selling, general and administrative 15,703 15,065 60,357 61,373 Research and de

REFINITIV STREETEVENTS EDITED TRANSCRIPT SPPI.OQ - Q4 2020 Spectrum Pharmaceuticals Inc Earnings Call EVENT DATE/TIME: MARCH 30, 2021 / 8:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2021 Refinitiv. All rights reserved. Republica

EX-99.2 3 sppi-usqtranscriptx2021.htm EX-99.2 REFINITIV STREETEVENTS EDITED TRANSCRIPT SPPI.OQ - Q4 2020 Spectrum Pharmaceuticals Inc Earnings Call EVENT DATE/TIME: MARCH 30, 2021 / 8:30PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2021 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited withou

Description of Equity Securities Registered under Section 12 of the Exchange Act.

Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK WE MAY OFFER General Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The following description of our common stock and preferred stock, together with the additional information included in any applicable prospectus supplements or rel

Subsidiaries of Registrant.

EXHIBIT 21.1 List of Subsidiaries SUBSIDIARY/AFFILIATE NAME INCORPORATION Spectrum Oncology Private Limited India Spectrum Pharmaceuticals International Holdings, LLC Delaware Allos Therapeutics, Inc. Delaware Spectrum Pharmaceuticals Cayman, L.P. (1% Spectrum Pharmaceuticals International Holdings, LLC and 99% Spectrum Pharmaceuticals, Inc.) Cayman Islands Spectrum Pharmaceuticals, B.V. Netherlan

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update Poziotinib receives Fast Track Designation from FDA Preliminary safety and efficacy data for poziotinib twice daily dosing (BID) demonstrate

Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update Poziotinib receives Fast Track Designation from FDA Preliminary safety and efficacy data for poziotinib twice daily dosing (BID) demonstrates improved anti-tumor activity and reduced toxicity relative to once daily dosing FDA has scheduled the pre-approval inspection at the ROLONTIS® (eflapegrastim) manufacturing facility for May 2021 Management to host webcast and conference call today at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Spectrum Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 84763A108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule i

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA s

EX-99.1 Exhibit 99.1 Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients with EGFR exon 20 in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Pharmaceuticals Appoints Nora Brennan to Board of Directors

EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Appoints Nora Brennan to Board of Directors HENDERSON, Nevada – December 14, 2020 - Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms. Elizabeth Czerepak, who retired fro

Up to $60,000,000 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237319 PROSPECTUS SUPPLEMENT (To Prospectus dated May 8, 2020) Up to $60,000,000 Common Stock This sales agreement prospectus relates to the issuance and sale of shares of our common stock having an aggregate offering price of up to $60.0 million from time to time through our sales agents, Cantor Fitzgerald & Co., H.C. W

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 SPECTRUM PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 S

FDA deferred action on the BLA for ROLONTIS® (eflapegrastim) due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 i

EX-99.1 2 exhibit99120200930.htm EX-99.1 Spectrum Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Update FDA deferred action on the BLA for ROLONTIS® (eflapegrastim) due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations

Joint Filer Agreement, dated as of August 18, 2020, between Spectrum Pharmaceuticals, Inc. and Spectrum Pharmaceuticals Cayman, L.P.

EX-99.1 EXHIBIT 99.1 JOINT FILER AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that a single Schedule 13D, or any amendment thereto, relating to the equity securities of CASI Pharmaceuticals, Inc., a Delaware corporation, shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as Exh

CASI / CASI Pharmaceuticals, Inc. / SPECTRUM PHARMACEUTICALS INC - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* CASI Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 14757U109 (CUSIP Number) Kurt Gustafson Executive Vice President and Chief Financial Officer Spectrum Pharmaceuticals, Inc. 1150

SPPI / Spectrum Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update Recently announced positive topline results in HER2 exon 20 insertion mutations from Cohort 2 of the poziotinib ZENITH20 trial Company is in process of reques

Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update Recently announced positive topline results in HER2 exon 20 insertion mutations from Cohort 2 of the poziotinib ZENITH20 trial Company is in process of requesting a pre-NDA meeting with the FDA seeking an indication for second-line NSCLC patients with HER2 exon 20 insertion mutations BLA for ROLONTIS® (eflapegrastim) under active FDA review - PDUFA date of October 24, 2020 Management to host webcast and conference call today at 4:30 p.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTR

Spectrum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

EX-99.1 EXHIBIT 99.1 Spectrum Pharmaceuticals Announces Pricing of Public Offering of Common Stock HENDERSON, Nev., July 30, 2020 — Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the pricing of an underwritten public offering of 21,666,667 shares of its common stock at a publ

Underwriting Agreement by and between Spectrum Pharmaceuticals, Inc. and Jefferies LLC, dated July 29, 2020

EX-1.1 Exhibit 1.1 21,666,667 Shares of Common Stock Spectrum Pharmaceuticals, Inc. UNDERWRITING AGREEMENT July 29, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwr

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 SPECTRUM PHARMACEUTICALS, INC.

21,666,667 Shares Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-237319 PROSPECTUS SUPPLEMENT (to prospectus dated May 8, 2020) 21,666,667 Shares Common Stock We are offering 21,666,667 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on the Nasdaq Global Select Market under the s

Shares Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-237319 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the acco

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock

EX-99.1 EXHIBIT 99.1 Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock HENDERSON, Nev., July 29, 2020 — Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All o

Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT

EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT HENDERSON, Nev.—July 27, 2020—Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therap

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 SPECTRUM PHARMACEUTICALS, INC.

- 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact

- S-8

As filed with the Securities and Exchange Commission on June 22, 2020 Registration No.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

First Amendment to the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

EX-10.1 2 firstamendmentto2018pl.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO THE SPECTRUM PHARMACEUTICALS, INC. 2018 LONG-TERM INCENTIVE PLAN WHEREAS, Spectrum Pharmaceuticals, Inc. (the “Employer”) adopted the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the “Plan”) effective as of June 18, 2020; WHEREAS, the Employer has the ability to amend the Plan pursuant to Article 7(a

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECT

Power of Attorney.

Exhibit 24.2 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that the individual whose signature appears below constitutes and appoints Kurt A. Gustafson and Keith McGahan, and each of them acting individually, as his true and lawful attorneys-in-fact and agent, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead

Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update BLA for ROLONTIS® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy

Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update BLA for ROLONTIS® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to host webcast and conference call today at 4:30 p.

- S-3/A

As filed with the Securities and Exchange Commission on May 7, 2020 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

-

May 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Alan Campbell 100 F Street, NE Washington, D.C. 20549 Re: Spectrum Pharmaceuticals, Inc. Registration Statement on Form S‑3 File No. 333-237319 (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amen

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2020 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors

EX-99.1 2 d910687dex991.htm EX-99.1 Exhibit 99.1 Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors HENDERSON, Nev. – April 23, 2020 - Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. Mr. Fischer fills a vacancy left by Mr. R

Definitive Proxy Statement on Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

SPPI / Spectrum Pharmaceuticals, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

SPPI / Spectrum Pharmaceuticals, Inc. S-3 - - S-3

As filed with the Securities and Exchange Commission on March 20, 2020 Registration No.

Form of Stock Appreciation Rights Agreement under the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan

Exhibit 10.1 SPECTRUM PHARMACEUTICALS, INC. TERM SHEET FOR 2018 LONG-TERM INCENTIVE PLAN STOCK APPRECIATION RIGHTS AWARD Spectrum Pharmaceuticals, Inc. hereby grants to the Participant named below stock appreciation rights (the “SARs”) covering the number of shares of Common Stock specified below, at the exercise price specified below, and on the terms and subject to the conditions set forth in th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Eighth Amendment to Lease, dated October 10, 2018, by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company LLC.

leaseamend8irvinecompany

Subsidiaries of Registrant.

EXHIBIT 21.1 List of Subsidiaries SUBSIDIARY/AFFILIATE NAME INCORPORATION Spectrum Oncology Private Limited India Spectrum Pharmaceuticals International Holdings, LLC Delaware Allos Therapeutics, Inc. Delaware Spectrum Pharmaceuticals Cayman, L.P. (1% Spectrum Pharmaceuticals International Holdings, LLC and 99% Spectrum Pharmaceuticals, Inc.) Cayman Islands Spectrum Pharmaceuticals, B.V. Netherlan

Form of Indemnification Agreement of Spectrum Pharmaceuticals, Inc.

Exhibit 10.11 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”), dated [DATE], is by and between Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [NAME OF DIRECTOR/OFFICER] (“Indemnitee”). RECITALS WHEREAS, [Indemnitee is a director or an officer of the Company / the Company expects Indemnitee to join the Company as a director or officer]; WHERE

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name o

Amended and Restated Spectrum Pharmaceuticals, Inc. 2009 Employee Stock Purchase Plan.

Exhibit 10.12 AMENDED AND RESTATED SPECTRUM PHARMACEUTICALS, INC. 2009 EMPLOYEE STOCK PURCHASE PLAN This EMPLOYEE STOCK PURCHASE PLAN (the “Plan”) is hereby established by Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”) as of March 23, 2009. The Plan was amended and restated as of September 21, 2018. ARTICLE I PURPOSE OF THE PLAN 1.1 Purpose. The Company has determined that

Seventh Amendment to Lease, dated August 7, 2018, by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company LLC.

leaseamend7irvinecompany DocuSign Envelope ID: 48C8E935-A438-439F-97A1-A1DF19894B39 SEVENTH AMENDMENT TO LEASE I.

Description of Equity Securities Registered under Section 12 of the Exchange Act.

Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK WE MAY OFFER General Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. The following description of our common stock and preferred stock, together with the additional information included in any applicable prospectus supplements or rel

Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update BLA for ROLONTIS® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepte

EX-99.1 2 exhibit991q42019.htm EXHIBIT 99.1 Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update BLA for ROLONTIS® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11th Annual Congress on Pulmonary and Respiratory Medicine in Ams

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

SPPI / Spectrum Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Spectrum Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 84763A108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is

SPPI / Spectrum Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Spectrum Pharmaceuticals A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology Joe Turgeon | President and CEO January 2020 | Investor Presentation Safe Harbor Statement This presentation contains forward-looking statements

a2020spectrumcorporatede Spectrum Pharmaceuticals A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology Joe Turgeon | President and CEO January 2020 | Investor Presentation Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially.

Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EG

Media Contact: Spectrum Pharmaceuticals, Inc. Shiv Kapoor Vice President, Strategic Planning & Investor Relations 702-835-6300 [email protected] Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients w

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 S

Executive Employment Agreement, dated as of June 19, 2019, by and between Spectrum Pharmaceuticals, Inc. and Dr. Francois Lebel.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is dated as of June 19, 2019 by and between Spectrum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Dr. Francois Lebel (“Executive”). WHEREAS, the Company desires to employ Executive as Executive Vice President and Chief Medical Officer; and WHEREAS, the Company and Executive desi

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTR

Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update

COMPANY CONTACTS Shiv Kapoor Vice President, Strategic Planning & Investor Relations 702-835-6300 InvestorRelations@sppirx.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 SPECTRUM PHARMACEUTICALS INC (Exact name of registrant as specified in its charter) Delaware 001-35006 93-0979187 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

SPPI / Spectrum Pharmaceuticals, Inc. 11-K - - 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2019 SPECTRUM PHARMACEUTICALS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 SPECTRUM PHARMACEUTICALS, INC.

Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update

COMPANY CONTACTS Shiv Kapoor Vice President, Strategic Planning & Investor Relations 702-835-6300 InvestorRelations@sppirx.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35006 SPECT

SPPI / Spectrum Pharmaceuticals, Inc. DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

SPPI / Spectrum Pharmaceuticals, Inc. DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Form of Subordinated Debt Securities Indenture. (Filed as Exhibit 4.4 to Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on April 5, 2019, and incorporated herein by reference).

Exhibit 4.4 SPECTRUM PHARMACEUTICALS, INC. SUBORDINATED DEBT SECURITIES INDENTURE Dated as of Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Section 2.03 D

Controlled Equity Offering Sales Agreement, dated as of April 5, 2019 among Registrant, Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC and B. Riley FBR, Inc.

Exhibit 1.2 SPECTRUM PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement April 5, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY 10171 Ladies and Gentlemen: Spectrum Pharmaceuticals, Inc., a Dela